ZIVOW
Income statement / Annual
Last year (2024), ZIVO Bioscience, Inc.'s total revenue was $157.22 K,
an increase of 468.61% from the previous year.
In 2024, ZIVO Bioscience, Inc.'s net income was -$13.38 M.
See ZIVO Bioscience, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$157.22 K |
$27.65 K |
$0.00 |
$0.00 |
$20.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$108.27 K
|
$16.04 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$48.95 K
|
$11.61 K
|
$0.00
|
$0.00
|
$20.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.31
|
0.42
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$3.13 M
|
$1.38 M
|
$2.24 M
|
$2.12 M
|
$3.75 M
|
$2.31 M
|
$2.81 M
|
$2.38 M
|
$788.97 K
|
$1.03 M
|
| General & Administrative Expenses |
$10.28 M
|
$5.90 M
|
$6.49 M
|
$6.93 M
|
$4.82 M
|
$6.05 M
|
$3.32 M
|
$3.95 M
|
$2.70 M
|
$2.02 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.28 M
|
$5.90 M
|
$6.49 M
|
$6.93 M
|
$4.82 M
|
$6.05 M
|
$3.32 M
|
$3.95 M
|
$2.70 M
|
$2.02 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$13.41 M
|
$7.27 M
|
$8.73 M
|
$9.05 M
|
$8.58 M
|
$8.35 M
|
$6.13 M
|
$6.33 M
|
$3.49 M
|
$3.06 M
|
| Cost And Expenses |
$13.52 M
|
$7.29 M
|
$8.73 M
|
$9.05 M
|
$8.58 M
|
$8.35 M
|
$6.13 M
|
$6.33 M
|
$3.49 M
|
$3.06 M
|
| Interest Income |
$0.00
|
$0.00
|
$13.32 K
|
$233.28 K
|
$0.00
|
$3.16 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$22.94 K
|
$514.17 K
|
$13.32 K
|
$233.28 K
|
$550.05 K
|
$3.16 M
|
$8.10 M
|
$1.83 M
|
$986.19 K
|
$720.71 K
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$4.00
|
-$407.49 K
|
$8.56 M
|
$8.35 M
|
$18.75 K
|
$18.75 K
|
$25.00 K
|
$25.00 K
|
| EBITDA |
-$13.36 M |
-$7.26 M |
-$8.73 M |
-$9.05 M |
-$550.05 K |
-$8.35 M |
-$6.13 M |
-$6.33 M |
-$3.49 M |
-$3.06 M |
| EBITDA Ratio |
-84.99
|
-262.68
|
0
|
0
|
-27.5
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-84.99
|
-262.68
|
0
|
0
|
-427.78
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$22.94 K
|
-$514.17 K
|
-$13.32 K
|
-$110.76 K
|
-$550.05 K
|
-$3.16 M
|
-$8.50 M
|
-$3.71 M
|
-$2.57 M
|
-$2.73 M
|
| Income Before Tax |
-$13.38 M
|
-$7.78 M
|
-$8.75 M
|
-$9.16 M
|
-$9.11 M
|
-$11.51 M
|
-$14.64 M
|
-$10.04 M
|
-$6.06 M
|
-$5.79 M
|
| Income Before Tax Ratio |
-85.13
|
-281.27
|
0
|
0
|
-455.29
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$233.28 K
|
$0.00
|
$3.16 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$13.38 M
|
-$7.78 M
|
-$8.75 M
|
-$9.40 M
|
-$9.66 M
|
-$14.67 M
|
-$14.64 M
|
-$10.04 M
|
-$6.06 M
|
-$5.79 M
|
| Net Income Ratio |
-85.13
|
-281.27
|
0
|
0
|
-482.79
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.92 |
-4.6 |
-5.58 |
-7.4 |
-11.41 |
-25.47 |
-44.84 |
-34.6 |
-21.73 |
-21.22 |
| EPS Diluted |
-3.92 |
-4.6 |
-5.57 |
-7.39 |
-11.41 |
-25.47 |
-44.84 |
-34.6 |
-21.73 |
-21.22 |
| Weighted Average Shares Out |
$3.41 M
|
$1.69 M
|
$1.57 M
|
$1.27 M
|
$846.21 K
|
$575.83 K
|
$326.41 K
|
$290.09 K
|
$278.84 K
|
$272.80 K
|
| Weighted Average Shares Out Diluted |
$3.41 M
|
$1.69 M
|
$1.57 M
|
$1.27 M
|
$846.21 K
|
$575.83 K
|
$326.41 K
|
$290.09 K
|
$278.84 K
|
$272.80 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
